KEYTRUDA 25 mg/mL concentrate for solution for infusion, [68GA]PSMA-HBED-CC clinical trials

An open label, single-arm, phase 2 study of neoadjuvant PEMbrolizumab before radical PROstatectomy (PEM-PRO) in high-risk prostate cancer patients

This study is looking at a new way to treat men with high-risk prostate cancer before surgery. It uses a drug called Pembrolizumab (Keytruda) to see if it can reduce the spread of cancer to lymph nodes, aiming for better outcomes than current treatments.